Influenza A/H1N1 in pediatric oncology patients

Amit Dotan1, Shalom Ben-Shimol, Yariv Fruchtman

  • 1*Pediatric Hemato-Oncology Unit †Pediatric Infectious Diseases Unit ‡Viral Clinical Laboratory, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Insights

Pandemic influenza A/H1N1 in immunocompromised children with cancer showed similar clinical features regardless of infection status. Early antiviral treatment contributed to good outcomes, highlighting the importance of immunization.

Area of Science:

  • Pediatric Oncology
  • Infectious Diseases
  • Epidemiology

Background:

  • Assessing clinical and epidemiological characteristics of pandemic influenza A/H1N1 in immunocompromised children with cancer.
  • Focus on children with solid tumors and hematological malignancies.

Purpose of the Study:

  • To determine the clinical and epidemiological features of pandemic influenza A/H1N1.
  • Evaluate outcomes in immunocompromised pediatric oncology patients.

Main Methods:

  • Prospective study during the H1N1 pandemic (August 2009-February 2010).
  • Included children with suspected H1N1 infection in a pediatric hematology-oncology unit.
  • Laboratory diagnosis via polymerase chain reaction (PCR) on nasopharyngeal wash specimens.

Main Results:

  • Identified 57 suspected H1N1 episodes in 40 children; 13% tested positive.
  • No significant demographic or clinical differences between H1N1-positive and negative children.
  • PCR-positive children had higher ICU admission and mechanical ventilation rates (P=0.03); one H1N1-positive patient died.

Conclusions:

  • Febrile immunocompromised pediatric oncology patients with or without influenza A/H1N1 presented similarly with good outcomes.
  • Early antiviral treatment and potentially lower virus virulence contributed to favorable results.
  • Encouraging influenza immunization in this vulnerable population is recommended.
Abstract

Related Concept Videos

Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
101
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
414
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
982
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
562
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K